United States Skin Cancer Drugs Market 2025 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Skin Cancer Drugs Market is estimated to reach high CAGR of 10.2% during the forecast period (2024-2031).

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/skin-cancer-drugs-market?sb

Key Development:

United States: Recent Skin Cancer Drug Developments

✅ In November 2025, Unloxcyt (cosibelimab‐ipdl) had its label expanded by the U.S. Food and Drug Administration (FDA) to include adults with metastatic or locally‐advanced cutaneous squamous cell carcinoma (CSCC) not amenable to curative surgery or radiation.

✅ In October 2025, Libtayo (cemiplimab‐rwlc) was approved by FDA as an adjuvant treatment for adult patients with high‐risk CSCC following surgery and radiation a first for preventing recurrence in that setting.

✅ In August 2025, Skinject a dissolvable microneedle patch delivering chemotherapy directly into basal cell carcinoma lesions completed a promising interim analysis, showing >60% clinical clearance in first half of targeted patients.

✅ In August 2025, the company behind Skinject announced that FDA accepted its Type‐C meeting request to pursue approval under the 505(b)(2) regulatory pathway signalling regulatory readiness to advance a non‐invasive skin‐cancer therapy.

✅ In May 2025, the acquisition of Checkpoint Therapeutics by Sun Pharma was completed granting Sun Pharma control over Unloxcyt and the entire onco‐dermal immunotherapy portfolio for advanced skin cancer.

Japan: Recent Skin Cancer / Skin‐Cancer Drug Developments

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=skin-cancer-drugs-market

✅ In April 2025, a consortium in Japan began a Phase III clinical trial for a novel drug candidate called RS5614 targeting malignant melanoma backed by subsidies from the country's biomedical‐innovation agency.

✅ In February 2025, a clinical‐pathological study of 237 Japanese skin‐cancer patients identified prognostic factors for cutaneous squamous cell carcinoma potentially informing future drug‐development, patient stratification, and therapy decisions.

✅ In 2025, a retrospective real‐world Japanese study on anti-PD‐1 therapy (e.g. Pembrolizumab or Nivolumab) in advanced cutaneous squamous cell carcinoma (cSCC) reported 57.1% overall response rate and manageable safety, supporting the relevance of checkpoint‐inhibitor immunotherapy for Asian patients.

✅ In 2025, standard systemic therapies (PD‐1 / immune checkpoint inhibitors) remain the mainstay for unresectable or recurrent skin cancers in Japan, with ongoing efforts to strengthen access and outcomes via immunotherapy use.

Key Players:

=> Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Sanofi S.A., Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd, Daiichi Sankyo Co., GlaxoSmithKline, among others.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/skin-cancer-drugs-market?sb

Key Segments:

By Cancer Type Segment

Melanoma leads with 35% share, driven by high incidence rates in developed regions, rising awareness, and significant R&D in targeted and immunotherapies. Non-melanoma skin cancers account for 30%, with basal cell carcinoma representing 18% and squamous cell carcinoma 12%, reflecting high prevalence but lower mortality rates. Merkel cell carcinoma holds 5%, supported by emerging targeted therapies and immunotherapy developments. The market outlook through 2031 shows increasing adoption of combination therapies and personalized treatment regimens across all skin cancer types.

By Drug Class

Chemotherapy holds 25% share, historically used across skin cancer types but gradually declining due to targeted and immunotherapy alternatives. Immunotherapy leads with 40%, driven by immune checkpoint inhibitors, monoclonal antibodies, and growing clinical success in melanoma and advanced non-melanoma cases. Targeted therapies account for 25%, supported by BRAF, MEK inhibitors, and other pathway-specific drugs that improve patient outcomes. Other drug classes make up 10%, including topical treatments, photodynamic therapy, and emerging experimental compounds. Growth opportunities lie in next-generation immunotherapies, combination therapies, and precision medicine approaches.

By End-User Segment

Hospitals lead with 50% share, reflecting high patient volume, availability of oncology specialists, and comprehensive treatment infrastructure. Clinics account for 20%, supported by outpatient treatments and dermatology-focused skin cancer management. Cancer research institutes represent 15%, contributing to clinical trials and new drug development. Other end-users make up 15%, including specialized oncology centers, academic medical centers, and tele-oncology services.

By Region

North America - 35% Share
North America leads with 35%, fueled by high skin cancer prevalence, advanced oncology infrastructure, and early adoption of immunotherapies and targeted therapies, especially in the U.S.

Europe - 25% Share
Europe holds 25%, supported by robust healthcare systems, increasing clinical trial activity, and growing adoption of innovative therapies across Germany, U.K., France, Italy, Spain, and neighboring countries.

Asia Pacific - 20% Share
Asia Pacific accounts for 20%, driven by rising skin cancer awareness, expanding healthcare access, and increasing investment in oncology R&D in China, Japan, India, and Southeast Asia.

Latin America - 10% Share
Latin America holds 10%, supported by government healthcare initiatives, rising awareness, and growing availability of oncology treatments in Brazil, Mexico, and surrounding countries.

Middle East & Africa - 10% Share
The Middle East & Africa represent 10%, fueled by increasing healthcare infrastructure investments, private oncology clinics, and the introduction of advanced treatment options in GCC countries, South Africa, and other emerging markets.

FAQ

Q: What is the growth rate of the Skin Cancer Drugs Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 10.2% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.